Company news: Amgen and Eli Lilly

Share this article:

Amgen's bone drug denosumab won approval for two new indications yesterday, both under the brand name Prolia: to increase bone mass in breast cancer patients on aromatase inhibitor therapy, and for prostate cancer patients undergoing androgen-deprivation therapy. Denosumab is also sold under the brand name Xgeva for reducing fractures and other bone problems in patients with bone metastases from solid tumors. Amgen is studying the drug for other uses, as well.

Eli Lilly said using patient navigators to guide subjects through the treatment process, as well as taking into account language and ethnic considerations of potential participants, can increase minority involvement in clinical trials. In a lung cancer study that began with 19% minority representation, after the interventions were introduced, minority participation among remaining enrollees increased to 43%.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.